High-intensity meropenem combinations with polymyxin B: New strategies to overcome carbapenem resistance in Acinetobacter Baumannii

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 1, 2017, Pages 153-165

  Lenhard, Justin R ^a,b   Bulitta, Jürgen B ^a,c   Connell, Terry D ^d   King Lyons, Natalie ^d   Landersdorfer, Cornelia B ^e   Cheah, Soon Ee ^e   Thamlikitkul, Visanu ^f   Shin, Beom Soo ^g   Rao, Gauri ^a   Holden, Patricia N ^a   Walsh, Thomas J ^h   Forrest, Alan ^a,i   Nation, Roger L ^e   Li, Jian ^e   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b California Northstate College of Pharmacy   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e MONASH UNIVERSITY   (Australia)

^f MAHIDOL UNIVERSITY   (Thailand)

^g Catholic University of Daegu   (South Korea)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; MEROPENEM; POLYMYXIN B; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; HOLLOW FIBER; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; THEORETICAL MODEL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; POLYMYXIN B; THIENAMYCINS;

EID: 85014578475     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw355     Document Type: Article

References (67)

1. Kim UJ, Kim HK, An JH et al. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J 2014; 50: 37-44.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82.
3. Ahmed NH, Hussain T, Biswal I. Antimicrobial resistance of bacterial isolates from respiratory secretions of ventilated patients in a multi-specialty hospital. Avicenna J Med 2015; 5: 74-8.
4. El-Saed A, Balkhy HH, Al-Dorzi HM et al. Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilatorassociated pneumonia in an adult intensive care unit in Saudi Arabia. Int J Infect Dis 2013; 17: e696-701.
5. Walkey AJ, Reardon CC, Sulis CA et al. Epidemiology of ventilatorassociated pneumonia in a long-term acute care hospital. Infect Control Hosp Epidemiol 2009; 30: 319-24.
6. Inchai J, Pothirat C, Liwsrisakun C et al. Ventilator-associated pneumonia: epidemiology and prognostic indicators of 30-day mortality. Jpn J Infect Dis 2015; 68: 181-6.
7. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
8. Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11: 15-23.
9. Norrby SR, Newell PA, Faulkner KL et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 Suppl A: 207-23.
10. Schmutzhard E, Williams KJ, Vukmirovits G et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995; 36 Suppl A: 85-97.
11. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38: 523-37.
12. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000; 22: 191-4.
13. Mouton JW, Touzw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.
14. Smith CA, Antunes NT, Stewart NK et al. Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii. Chem Biol 2013; 20: 1107-15.
15. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49: 1337-9.
16. Jaruratanasirikul S, Kositpantawong N, Jullangkoon M et al. Pharmacodynamics of meropenem in critically ill patients with ventilatorassociated pneumonia. J Med Assoc Thai 2013; 96: 1283-9.
17. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46: 1171-8.
18. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
19. Lee HJ, Bergen PJ, Bulitta JB et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57: 3738-45.
20. Hagihara M, Housman ST, Nicolau DP et al. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58: 874-9.
21. Liu Q, LiW, Feng Y et al. Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis. PLoS ONE 2014; 9: e98091.
22. Cai Y, Chai D, Wang R et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67: 1607-15.
23. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn Microbiol Infect Dis 2009; 63: 228-32.
24. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
25. Dubrovskaya Y, Prasad N, Lee Y et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015; 70: 1903-7.
26. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59: 88-94.
27. Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-84.
28. Cannon JP, Lee TA, Clark NM et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69: 2043-55.
29. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
30. Woodford N, Ellington MJ, Coelho JM et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 2006; 27: 351-3.
31. Gadsby NJ, McHugh MP, Russell CD et al. Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clin Microbiol Infect 2015; 21: 788.e1-e13.
32. Lenhard JR, von EiffC, Hong IS et al. Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype. Antimicrob Agents Chemother 2015; 59: 1347-51.
33. Ly NS, Bulitta JB, Rao GG et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 2015; 70: 1434-42.
34. Munz MR, Bulitta JB, Höhl R et al. Individualizing meropenem prolonged infusions in intensive care unit patients via population modeling of renal function and infection biomarkers over time. In: Paracelsus Science Get Together, Nürnberg, Germany, 2015.
35. Cheah SE, Bulitta JB, Li J et al. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 2014; 92: 177-82.
36. Blaser J. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 1985; 15 Suppl A: 125-30.
37. Dudhani RV, Turnidge JD, Nation RL et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65: 1984-90.
38. Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev 2013; 65: 1053-90.
39. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
40. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62.
41. Bulitta JB, Ly NS, Yang JC et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 46-56.
42. Bulitta JB, Landersdorfer CB, Forrest A et al. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 2011; 12: 2044-61.
43. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre-and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
44. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 2011; 13: 212-26.
45. Tsuji BT, Okusanya OO, Bulitta JB et al. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 2011; 52 Suppl 7: S513-9.
46. Bulitta JB, Okusanya OO, Forrest A et al. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents Chemother 2013; 57: 498-507.
47. Landersdorfer CB, Ly NS, Xu H et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013; 57: 2343-51.
48. Bulitta JB, Ly NS, Landersdorfer CB et al. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother 2015; 59: 2315-27.
49. Yadav R, Landersdorfer CB, Nation RL et al. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59: 2286-98.
50. CraigWA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
51. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
52. EUCAST. Breakpoint Tables for Interpretation ofMICs and Zone Diameters, Version 5.0, April 2015. http://www.eucast.org/clinical_breakpoints/.
53. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010; 51: 79-84.
54. Kaye KS, Pogue JM, Tran TB et al. Agents of last resort: polymyxin resistance. Infect Dis Clin North Am 2016; 30: 391-414.
55. Cotta MO, Gowen B, TruloffN et al. Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring. Infect Dis (Lond) 2015; 47: 739-42.
56. Bulik CC, Quintiliani R Jr, Samuel Pope J et al. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis-a review of 3 cases. Respiratory Medicine CME 2010; 3: 146-9.
57. Taccone FS, Cotton F, Roisin S et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-31.
58. Tam VH, Louie A, Deziel MR et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007; 51: 744-7.
59. Pike M, Saltiel E. Colistin-and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. J Pharm Pract 2014; 27: 554-61.
60. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006; 222: 114-24.
61. Merrem Package Insert. Wilmington, DE, USA: AstraZeneca Pharmaceuticals, Revised December 2013.
62. Zivanovic D, Stanojlovic O, Susic V et al. The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilastatin in rats. Acta Neurol Belg 2004; 104: 20-6.
63. Maidhof H, Johannsen L, Labischinski H et al. Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 1989; 171: 2252-7.
64. Bulitta JB, Li J, Poudyal A et al. Quantifying synergy of colistin combinations against MDR Gram-negatives by mechanism-based models. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2009. Abstract A1-573. American Society for Microbiology, Washington, DC, USA.
65. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 1993; 175: 5798-805.
66. Kadurugamuwa JL, LamJS, Beveridge TJ. Interaction of gentamicinwith the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob Agents Chemother 1993; 37: 715-21.
67. Bulitta JB, Duffull SB, Kinzig-Schippers M et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-507.